Clinical trial · Observational
Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer
Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer Treated With Conventional Radiotherapy
NCT05252065CI-TRIAL-00056681unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Calculating which cardiac substructure accepting with the highest radiation dose by conventional radiotherapy, then to investigate the relationship between the changes of global longitudinal strain or cardiac magnetic resonance imaging and cardiac biomarkers and the certain cardiac substructure for stage N2-3 non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with NSCLC
- description
- all stage N2-3 non-small cell lung cancer patients receive intensity-modulated radiotherapy (IMRT). The prescription dose of PTV is 60-70Gy.
- interventionNames
- Other: Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging
Primary outcomes (3)
- measure
- Concentration of Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP
- timeFrame
- through study completion, an average of 1 year
- description
- These levels are measured with the Siemens ADVIA Centaur XP Immunoassay System, normal ranges of Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are 0-0.03 ng/mL, 0-0.01 ng/mL, 0-0.04 ng/mL, 0-100 pg/mL, and 0-125pg/mL respectively
- measure
- Global longitudinal strain value
- timeFrame
- through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients at TNM stage N2-N3 NSCLC confirmed by histopathology or cytology using IASLC International TNM staging standard (8th edition) 2. KPS score \>80; Aged 18 to 75 year-old 3. No contraindications to radiotherapy 4. No history of heart disease before treatment 5. Patients receiving intensity modulated radiation therapy (IMRT) 6. Patients receiving PTV at a prescription dose of 60-70Gy by IMRT 7. Patients receiving radiotherapy alone and concurrent chemoradiotherapy Exclusion Criteria: 1. Patients with pleural effusion 2. Patients with serious medical illness or infection 3. Patients with acute myocardial infarction within 6 months 4. In patients with NYHA grade 3-4, baseline LVEF before radiotherapy is below 59% 5. Patients with congenital heart diseases, valvular diseases and arrhythmia 6. Patients with pericardial effusion 7. Patients receiving immunotherapy and drug targeted therapy 8. Patients with a history of anthracycline use
References
Publications (0)
Data not yet available
No reference posted for this study.